MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea · Delayed Price · Currency is KRW

387.00

+24.00 (6.61%)

At close: Jul 31, 2026

-77.54% (1Y)

Market Cap	16.32B -75.7%
Revenue (ttm)	10.45B -24.2%
Net Income	-12.86B
EPS	-340.35
Shares Out	42.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,648
Open	370.00
Previous Close	363.00
Day's Range	355.00 - 390.00
52-Week Range	340.00 - 2,180.00
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 42

Stock Exchange KOSDAQ

Ticker Symbol 142760

Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements